Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced 1Q2024 results and we remind investors that the company has begun Phase I trials on its Gemini project and has funding needs met through 2024, which is extremely positive for a clinical stage company.
